$NVO

Pfizer faces patent cliffs and COVID vaccine decline, betting on oncology and obesity drug pipelines to drive future growth amid acquisition integration challenges.

Amgen and GSK join TrumpRx.gov offering up to 80% and 10-55% discounts respectively, expanding the platform to 54 drugs amid Trump administration pricing pressure.

BIO-Europe Spring 2026 in Lisbon expects 3,700+ attendees, 20,000+ meetings, and robust partnering activity as global biopharma industry seeks strategic deals and investment opportunities.

Novo Nordisk has repurchased 6.6 million B shares for DKK 1.78 billion, progressing through its DKK 15 billion share buyback program launched in February 2026.

Eli Lilly dominates weight-loss pharmaceuticals with 45% 2025 revenue growth, maintaining market lead despite competitor advances due to years-long regulatory timelines.

Eli Lilly commits $3 billion to decade-long China expansion, targeting 141 million diabetics and 600 million overweight adults amid intense domestic competition.

Novo Holdings achieved 9.2% portfolio return in 2025 but total AUM fell 35% to DKK 694B, primarily due to Novo Nordisk valuation decline.

Eli Lilly's orforglipron oral GLP-1 drug offers no food restrictions and dual obesity-diabetes approval potential, threatening Novo Nordisk's oral Wegovy dominance.

BLKBRD Asset Management fully exits $18M Hims & Hers position in Q4 2025, just before company reconciles with Novo Nordisk.

Pfizer and Novo Nordisk trade at 9x-10.5x forward earnings with deep pipelines offering long-term value potential despite recent underperformance.

European natural gas surged 68% weekly to 3-year highs amid US-Israeli military actions; weak economic data and political divisions compound energy crisis risks.

Hims & Hers surges 40% after Novo Nordisk partnership resolves litigation, enabling authorized distribution of Wegovy and Ozempic. Stock trades under 20x forward P/E.

Roche's giredestrant failed to meet primary endpoint in Phase 3 breast cancer trial, causing 5% stock decline. Company plans adjuvant trial readout in 2027.

Hims & Hers and Novo Nordisk end legal battle, partnering to distribute weight-loss drugs via telehealth. Stock surges 48.67% despite mixed guidance.

U.S. stock futures tumbled as crude oil surged 13-15% amid Iran tensions. Hims & Hers soared 49% on Novo Nordisk settlement; UniQure gained 36% on FDA clarity.

Novo Nordisk leads GLP-1 market but faces Eli Lilly competition; Amgen's MariTide offers differentiated approach with less portfolio risk.

Eli Lilly's GLP-1 success masks valuation risks; P/E of 44 leaves little room for competitive pressure and patent cliff execution.

Novo Nordisk stock trades cheap but faces execution headwinds versus Eli Lilly's superior operational performance in the booming GLP-1 market.

Pfizer wins NMPA approval for weight-loss drug ecnoglutide in China, achieving 15.4% average weight loss in trials, intensifying competition as Novo Nordisk's Wegovy faces patent expiry.

Roche's obesity drug petrelintide achieved 10.7% weight loss in Phase 2 trials but significantly trails GLP-1 rivals Novo Nordisk and Eli Lilly, triggering sharp stock declines.